Drug intelligence / Profile preview

NK-043

Development stage: Preclinical
Lead developer: Shanghai Enkai Cell Technology
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

NK-043 is an investigational natural killer (NK) cell therapy being developed by Shanghai NK Cell Technology for the treatment of various cancers. The therapy is based on the company's proprietary NKR-NK platform, which involves engineering NK cells to express specific natural killer receptors (NKR) to improve tumor recognition and cytotoxic activity. Currently in the discovery or preclinical stage, NK-043 is intended to target unspecified tumor types. Technical details regarding the specific receptors or molecular targets utilized in this candidate have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on NK-043.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NK-043.

Explore the full profile